This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Checking in with a prescriber of retinal disease treatments Eylea and Vabysmo.
Ticker(s): REGN, RHHBYWho's the expert?
Institution: Duke Eye Center
- treats 500 patients with geographic atrophy.
- Very familiar with the potential use of intravitreal pegcetacoplan for geographic atrophy
- has seen the publicly available data for both the Phase 2 and Phase 3 data supporting development of pegcetacoplan for treatment of GA and is familiar with the recently released 24-month results of pegcetacoplan in Phase 3 DERBY and OAKS Studies
Interview Goalto discuss the current standard of care and the use of Eylea from Regeneron and Vabysmo from Roche for the treatment of retinal diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
